Study summary

Dato-DXd helped people live about 5 months longer than chemotherapy

TROPION-Breast02 trial (Dato-DXd) · 644 people, phase 3 · Published April 2026, Annals of Oncology

23.7months median survival, vs 18.7 with chemotherapy

What was tested

Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate aimed at TROP2, against chemotherapy as first treatment for advanced TNBC when immunotherapy was not an option.

What they found

What it means

A second antibody-drug conjugate with a survival benefit in first-line TNBC.

Ann Oncol, via PubMed ↗ Trial record NCT05374512 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.